Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 28. More products

LAMOTRIGINE

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (N03AX) — coverage varies; not interchangeable

  • Topiramate (Topamax Sprinkle): general benefit, Limited Use 321, Not a benefit
  • Brivaracetam (Brivlera): limited Use 548
  • Cenobamate (Xcopri): limited Use 719
  • Lacosamide (Vimpat): limited Use 430
  • Levetiracetam (PDP-Levetiracetam): limited Use 473, Limited Use 640, 705
  • Perampanel (Fycompa): limited Use 430, 564

14 more in the class list below

Apo-Lamotrigine · DIN 02245208 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Lamotrigine · DIN 02245208 Manufacturer: Apotex Inc.; listing date 2003-01-30 Health Canada: Marketed since 2002-03-18 · brand APO-LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 25 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Lamotrigine: Formulary list price $0.0698/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0698 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69223 · Verify on the e-Formulary ↗ (DIN 02245208)

Source record
DIN 02245208: Apo-Lamotrigine Raw flags: sec3=Y Item: 281200055; group id 432; item number 1079; lccId None; manufacturer id APX Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.0698; ministry $0.0698 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245208 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69223
Interchangeable products
Auro-Lamotrigine · DIN 02381354 · $0.0698 Jamp Lamotrigine · DIN 02542730 · $0.0698 Lamictal · DIN 02142082 · $0.0698 Lamotrigine · DIN 02343010 · $0.0698 Lamotrigine · DIN 02428202 · $0.0698 Mylan-Lamotrigine · DIN 02265494 · $0.0698 PMS-Lamotrigine · DIN 02246897 · $0.0698 Ratio-Lamotrigine · DIN 02243352 · $0.0698 Teva-Lamotrigine · DIN 02248232 · $0.0698
Shortage status: resolved shortage (ended 2020-01-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245208
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Lamotrigine · DIN 02381354 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Lamotrigine · DIN 02381354 Manufacturer: Auro Pharma Inc.; listing date 2012-08-27 Health Canada: Marketed since 2012-06-13 · brand AURO-LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 25 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Lamotrigine: Formulary list price $0.0698/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0698 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86718 · Verify on the e-Formulary ↗ (DIN 02381354)

Source record
DIN 02381354: Auro-Lamotrigine Raw flags: sec3=Y Item: 281200055; group id 432; item number 1079; lccId None; manufacturer id AUR Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.0698; ministry $0.0698 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02381354 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86718
Interchangeable products
Apo-Lamotrigine · DIN 02245208 · $0.0698 Jamp Lamotrigine · DIN 02542730 · $0.0698 Lamictal · DIN 02142082 · $0.0698 Lamotrigine · DIN 02343010 · $0.0698 Lamotrigine · DIN 02428202 · $0.0698 Mylan-Lamotrigine · DIN 02265494 · $0.0698 PMS-Lamotrigine · DIN 02246897 · $0.0698 Ratio-Lamotrigine · DIN 02243352 · $0.0698 Teva-Lamotrigine · DIN 02248232 · $0.0698
Shortage status: resolved shortage (ended 2024-08-27); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02381354
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Lamotrigine · DIN 02542730 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Lamotrigine · DIN 02542730 Manufacturer: Jamp Pharma Corporation; listing date 2024-08-30 Health Canada: Marketed since 2024-06-21 · brand JAMP LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 25 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Lamotrigine: Formulary list price $0.0698/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0698 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103127 · Verify on the e-Formulary ↗ (DIN 02542730)

Source record
DIN 02542730: Jamp Lamotrigine Raw flags: sec3=Y Item: 281200055; group id 432; item number 1079; lccId None; manufacturer id JPC Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.0698; ministry $0.0698 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02542730 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103127
Interchangeable products
Apo-Lamotrigine · DIN 02245208 · $0.0698 Auro-Lamotrigine · DIN 02381354 · $0.0698 Lamictal · DIN 02142082 · $0.0698 Lamotrigine · DIN 02343010 · $0.0698 Lamotrigine · DIN 02428202 · $0.0698 Mylan-Lamotrigine · DIN 02265494 · $0.0698 PMS-Lamotrigine · DIN 02246897 · $0.0698 Ratio-Lamotrigine · DIN 02243352 · $0.0698 Teva-Lamotrigine · DIN 02248232 · $0.0698
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02542730
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lamictal · DIN 02142082 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Lamictal (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Lamictal · DIN 02142082 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01 Health Canada: Marketed since 2002-06-14 · brand LAMICTAL · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 25 MG · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.0698 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17203 · Verify on the e-Formulary ↗ (DIN 02142082)

Source record
DIN 02142082: Lamictal Raw flags: sec3=Y Item: 281200055; group id 432; item number 1079; lccId None; manufacturer id GSK Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.5505; ministry $0.0698 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02142082 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17203
Interchangeable products
Apo-Lamotrigine · DIN 02245208 · $0.0698 Auro-Lamotrigine · DIN 02381354 · $0.0698 Jamp Lamotrigine · DIN 02542730 · $0.0698 Lamotrigine · DIN 02343010 · $0.0698 Lamotrigine · DIN 02428202 · $0.0698 Mylan-Lamotrigine · DIN 02265494 · $0.0698 PMS-Lamotrigine · DIN 02246897 · $0.0698 Ratio-Lamotrigine · DIN 02243352 · $0.0698 Teva-Lamotrigine · DIN 02248232 · $0.0698
Shortage status: resolved shortage (ended 2018-02-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02142082
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lamotrigine · DIN 02343010 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lamotrigine · DIN 02343010 Manufacturer: Sanis Health Inc.; listing date 2011-08-04 Health Canada: Marketed since 2010-02-16 · brand LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 25 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Lamotrigine: Formulary list price $0.0698/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0698 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82850 · Verify on the e-Formulary ↗ (DIN 02343010)

Source record
DIN 02343010: Lamotrigine Raw flags: sec3=Y Item: 281200055; group id 432; item number 1079; lccId None; manufacturer id SAI Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.0698; ministry $0.0698 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02343010 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82850
Interchangeable products
Apo-Lamotrigine · DIN 02245208 · $0.0698 Auro-Lamotrigine · DIN 02381354 · $0.0698 Jamp Lamotrigine · DIN 02542730 · $0.0698 Lamictal · DIN 02142082 · $0.0698 Lamotrigine · DIN 02428202 · $0.0698 Mylan-Lamotrigine · DIN 02265494 · $0.0698 PMS-Lamotrigine · DIN 02246897 · $0.0698 Ratio-Lamotrigine · DIN 02243352 · $0.0698 Teva-Lamotrigine · DIN 02248232 · $0.0698
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02343010
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lamotrigine · DIN 02428202 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lamotrigine · DIN 02428202 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-08-28 Health Canada: Marketed since 2014-10-08 · brand LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 25 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Lamotrigine: Formulary list price $0.0698/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0698 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91268 · Verify on the e-Formulary ↗ (DIN 02428202)

Source record
DIN 02428202: Lamotrigine Raw flags: sec3=Y Item: 281200055; group id 432; item number 1079; lccId None; manufacturer id SIV Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.0698; ministry $0.0698 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02428202 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91268
Interchangeable products
Apo-Lamotrigine · DIN 02245208 · $0.0698 Auro-Lamotrigine · DIN 02381354 · $0.0698 Jamp Lamotrigine · DIN 02542730 · $0.0698 Lamictal · DIN 02142082 · $0.0698 Lamotrigine · DIN 02343010 · $0.0698 Mylan-Lamotrigine · DIN 02265494 · $0.0698 PMS-Lamotrigine · DIN 02246897 · $0.0698 Ratio-Lamotrigine · DIN 02243352 · $0.0698 Teva-Lamotrigine · DIN 02248232 · $0.0698
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02428202
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Lamotrigine · DIN 02265494 · 25mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Lamotrigine · DIN 02265494 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2005-07-14 Health Canada: Marketed since 2009-10-22 · brand MYLAN-LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 25 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Lamotrigine: Formulary list price $0.0698/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0698 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75095 · Verify on the e-Formulary ↗ (DIN 02265494)

Source record
DIN 02265494: Mylan-Lamotrigine Raw flags: sec3=Y Item: 281200055; group id 432; item number 1079; lccId None; manufacturer id MYL Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.0698; ministry $0.0698 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02265494 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75095
Interchangeable products
Apo-Lamotrigine · DIN 02245208 · $0.0698 Auro-Lamotrigine · DIN 02381354 · $0.0698 Jamp Lamotrigine · DIN 02542730 · $0.0698 Lamictal · DIN 02142082 · $0.0698 Lamotrigine · DIN 02343010 · $0.0698 Lamotrigine · DIN 02428202 · $0.0698 PMS-Lamotrigine · DIN 02246897 · $0.0698 Ratio-Lamotrigine · DIN 02243352 · $0.0698 Teva-Lamotrigine · DIN 02248232 · $0.0698
Shortage status: resolved shortage (ended 2025-08-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02265494
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Lamotrigine · DIN 02245209 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Lamotrigine · DIN 02245209 Manufacturer: Apotex Inc.; listing date 2003-01-30 Health Canada: Marketed since 2017-08-04 · brand APO-LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 100 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Lamotrigine: Formulary list price $0.2787/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2787 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69224 · Verify on the e-Formulary ↗ (DIN 02245209)

Source record
DIN 02245209: Apo-Lamotrigine Raw flags: sec3=Y Item: 281200059; group id 432; item number 1080; lccId None; manufacturer id APX Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.2787; ministry $0.2787 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245209 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69224
Interchangeable products
Auro-Lamotrigine · DIN 02381362 · $0.2787 Jamp Lamotrigine · DIN 02542749 · $0.2787 Lamictal · DIN 02142104 · $0.2787 Lamotrigine · DIN 02343029 · $0.2787 Lamotrigine · DIN 02428210 · $0.2787 Mylan-Lamotrigine · DIN 02265508 · $0.2787 PMS-Lamotrigine · DIN 02246898 · $0.2787 Teva-Lamotrigine · DIN 02248233 · $0.2787
Shortage status: resolved shortage (ended 2023-09-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245209
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Lamotrigine · DIN 02381362 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Lamotrigine · DIN 02381362 Manufacturer: Auro Pharma Inc.; listing date 2012-08-27 Health Canada: Marketed since 2012-06-13 · brand AURO-LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 100 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Lamotrigine: Formulary list price $0.2787/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2787 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86719 · Verify on the e-Formulary ↗ (DIN 02381362)

Source record
DIN 02381362: Auro-Lamotrigine Raw flags: sec3=Y Item: 281200059; group id 432; item number 1080; lccId None; manufacturer id AUR Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.2787; ministry $0.2787 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02381362 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86719
Interchangeable products
Apo-Lamotrigine · DIN 02245209 · $0.2787 Jamp Lamotrigine · DIN 02542749 · $0.2787 Lamictal · DIN 02142104 · $0.2787 Lamotrigine · DIN 02343029 · $0.2787 Lamotrigine · DIN 02428210 · $0.2787 Mylan-Lamotrigine · DIN 02265508 · $0.2787 PMS-Lamotrigine · DIN 02246898 · $0.2787 Teva-Lamotrigine · DIN 02248233 · $0.2787
Shortage status: resolved shortage (ended 2024-10-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02381362
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Lamotrigine · DIN 02542749 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Lamotrigine · DIN 02542749 Manufacturer: Jamp Pharma Corporation; listing date 2024-08-30 Health Canada: Marketed since 2024-06-21 · brand JAMP LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 100 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Lamotrigine: Formulary list price $0.2787/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2787 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103128 · Verify on the e-Formulary ↗ (DIN 02542749)

Source record
DIN 02542749: Jamp Lamotrigine Raw flags: sec3=Y Item: 281200059; group id 432; item number 1080; lccId None; manufacturer id JPC Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.2787; ministry $0.2787 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02542749 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103128
Interchangeable products
Apo-Lamotrigine · DIN 02245209 · $0.2787 Auro-Lamotrigine · DIN 02381362 · $0.2787 Lamictal · DIN 02142104 · $0.2787 Lamotrigine · DIN 02343029 · $0.2787 Lamotrigine · DIN 02428210 · $0.2787 Mylan-Lamotrigine · DIN 02265508 · $0.2787 PMS-Lamotrigine · DIN 02246898 · $0.2787 Teva-Lamotrigine · DIN 02248233 · $0.2787
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02542749
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lamictal · DIN 02142104 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Lamictal (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Lamictal · DIN 02142104 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01 Health Canada: Marketed since 2002-05-22 · brand LAMICTAL · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 100 MG · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2787 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17201 · Verify on the e-Formulary ↗ (DIN 02142104)

Source record
DIN 02142104: Lamictal Raw flags: sec3=Y Item: 281200059; group id 432; item number 1080; lccId None; manufacturer id GSK Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $2.1990; ministry $0.2787 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02142104 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17201
Interchangeable products
Apo-Lamotrigine · DIN 02245209 · $0.2787 Auro-Lamotrigine · DIN 02381362 · $0.2787 Jamp Lamotrigine · DIN 02542749 · $0.2787 Lamotrigine · DIN 02343029 · $0.2787 Lamotrigine · DIN 02428210 · $0.2787 Mylan-Lamotrigine · DIN 02265508 · $0.2787 PMS-Lamotrigine · DIN 02246898 · $0.2787 Teva-Lamotrigine · DIN 02248233 · $0.2787
Shortage status: resolved shortage (ended 2018-05-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02142104
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lamotrigine · DIN 02343029 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lamotrigine · DIN 02343029 Manufacturer: Sanis Health Inc.; listing date 2011-08-04 Health Canada: Marketed since 2010-02-16 · brand LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 100 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Lamotrigine: Formulary list price $0.2787/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2787 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82851 · Verify on the e-Formulary ↗ (DIN 02343029)

Source record
DIN 02343029: Lamotrigine Raw flags: sec3=Y Item: 281200059; group id 432; item number 1080; lccId None; manufacturer id SAI Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.2787; ministry $0.2787 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02343029 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82851
Interchangeable products
Apo-Lamotrigine · DIN 02245209 · $0.2787 Auro-Lamotrigine · DIN 02381362 · $0.2787 Jamp Lamotrigine · DIN 02542749 · $0.2787 Lamictal · DIN 02142104 · $0.2787 Lamotrigine · DIN 02428210 · $0.2787 Mylan-Lamotrigine · DIN 02265508 · $0.2787 PMS-Lamotrigine · DIN 02246898 · $0.2787 Teva-Lamotrigine · DIN 02248233 · $0.2787
Shortage status: resolved shortage (ended 2025-05-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02343029
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lamotrigine · DIN 02428210 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lamotrigine · DIN 02428210 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-08-28 Health Canada: Marketed since 2014-10-08 · brand LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 100 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Lamotrigine: Formulary list price $0.2787/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2787 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91269 · Verify on the e-Formulary ↗ (DIN 02428210)

Source record
DIN 02428210: Lamotrigine Raw flags: sec3=Y Item: 281200059; group id 432; item number 1080; lccId None; manufacturer id SIV Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.2787; ministry $0.2787 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02428210 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91269
Interchangeable products
Apo-Lamotrigine · DIN 02245209 · $0.2787 Auro-Lamotrigine · DIN 02381362 · $0.2787 Jamp Lamotrigine · DIN 02542749 · $0.2787 Lamictal · DIN 02142104 · $0.2787 Lamotrigine · DIN 02343029 · $0.2787 Mylan-Lamotrigine · DIN 02265508 · $0.2787 PMS-Lamotrigine · DIN 02246898 · $0.2787 Teva-Lamotrigine · DIN 02248233 · $0.2787
Shortage status: resolved shortage (ended 2024-12-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02428210
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Lamotrigine · DIN 02265508 · 100mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Lamotrigine · DIN 02265508 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2005-07-14 Health Canada: Marketed since 2009-10-21 · brand MYLAN-LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 100 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Lamotrigine: Formulary list price $0.2787/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2787 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75096 · Verify on the e-Formulary ↗ (DIN 02265508)

Source record
DIN 02265508: Mylan-Lamotrigine Raw flags: sec3=Y Item: 281200059; group id 432; item number 1080; lccId None; manufacturer id MYL Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.2787; ministry $0.2787 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02265508 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75096
Interchangeable products
Apo-Lamotrigine · DIN 02245209 · $0.2787 Auro-Lamotrigine · DIN 02381362 · $0.2787 Jamp Lamotrigine · DIN 02542749 · $0.2787 Lamictal · DIN 02142104 · $0.2787 Lamotrigine · DIN 02343029 · $0.2787 Lamotrigine · DIN 02428210 · $0.2787 PMS-Lamotrigine · DIN 02246898 · $0.2787 Teva-Lamotrigine · DIN 02248233 · $0.2787
Shortage status: avoided shortage; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02265508
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Lamotrigine · DIN 02245210 · 150mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Lamotrigine · DIN 02245210 Manufacturer: Apotex Inc.; listing date 2003-01-30 Health Canada: Marketed since 2002-03-18 · brand APO-LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 150 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Lamotrigine: Formulary list price $0.4107/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4107 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69225 · Verify on the e-Formulary ↗ (DIN 02245210)

Source record
DIN 02245210: Apo-Lamotrigine Raw flags: sec3=Y Item: 281200060; group id 432; item number 1081; lccId None; manufacturer id APX Source form: Tab; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.4107; ministry $0.4107 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245210 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69225
Interchangeable products
Auro-Lamotrigine · DIN 02381370 · $0.4107 Jamp Lamotrigine · DIN 02542757 · $0.4107 Lamictal · DIN 02142112 · $0.4107 Lamotrigine · DIN 02343037 · $0.4107 Lamotrigine · DIN 02428229 · $0.4107 Mylan-Lamotrigine · DIN 02265516 · $0.4107 PMS-Lamotrigine · DIN 02246899 · $0.4107 Teva-Lamotrigine · DIN 02248234 · $0.4107
Shortage status: resolved shortage (ended 2023-10-05); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245210
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Lamotrigine · DIN 02381370 · 150mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Lamotrigine · DIN 02381370 Manufacturer: Auro Pharma Inc.; listing date 2012-08-27 Health Canada: Marketed since 2012-06-13 · brand AURO-LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 150 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Lamotrigine: Formulary list price $0.4107/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4107 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86720 · Verify on the e-Formulary ↗ (DIN 02381370)

Source record
DIN 02381370: Auro-Lamotrigine Raw flags: sec3=Y Item: 281200060; group id 432; item number 1081; lccId None; manufacturer id AUR Source form: Tab; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.4107; ministry $0.4107 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02381370 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86720
Interchangeable products
Apo-Lamotrigine · DIN 02245210 · $0.4107 Jamp Lamotrigine · DIN 02542757 · $0.4107 Lamictal · DIN 02142112 · $0.4107 Lamotrigine · DIN 02343037 · $0.4107 Lamotrigine · DIN 02428229 · $0.4107 Mylan-Lamotrigine · DIN 02265516 · $0.4107 PMS-Lamotrigine · DIN 02246899 · $0.4107 Teva-Lamotrigine · DIN 02248234 · $0.4107
Shortage status: resolved shortage (ended 2024-10-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02381370
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Lamotrigine · DIN 02542757 · 150mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Lamotrigine · DIN 02542757 Manufacturer: Jamp Pharma Corporation; listing date 2024-08-30 Health Canada: Marketed since 2024-06-21 · brand JAMP LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 150 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Lamotrigine: Formulary list price $0.4107/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4107 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103129 · Verify on the e-Formulary ↗ (DIN 02542757)

Source record
DIN 02542757: Jamp Lamotrigine Raw flags: sec3=Y Item: 281200060; group id 432; item number 1081; lccId None; manufacturer id JPC Source form: Tab; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.4107; ministry $0.4107 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02542757 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103129
Interchangeable products
Apo-Lamotrigine · DIN 02245210 · $0.4107 Auro-Lamotrigine · DIN 02381370 · $0.4107 Lamictal · DIN 02142112 · $0.4107 Lamotrigine · DIN 02343037 · $0.4107 Lamotrigine · DIN 02428229 · $0.4107 Mylan-Lamotrigine · DIN 02265516 · $0.4107 PMS-Lamotrigine · DIN 02246899 · $0.4107 Teva-Lamotrigine · DIN 02248234 · $0.4107
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02542757
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lamictal · DIN 02142112 · 150mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: innoviCares lists Lamictal (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Lamictal · DIN 02142112 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 1996-10-01 Health Canada: Marketed since 2002-03-07 · brand LAMICTAL · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 150 MG · company Glaxosmithkline inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.4107 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17160 · Verify on the e-Formulary ↗ (DIN 02142112)

Source record
DIN 02142112: Lamictal Raw flags: sec3=Y Item: 281200060; group id 432; item number 1081; lccId None; manufacturer id GSK Source form: Tab; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $3.2408; ministry $0.4107 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02142112 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=17160
Interchangeable products
Apo-Lamotrigine · DIN 02245210 · $0.4107 Auro-Lamotrigine · DIN 02381370 · $0.4107 Jamp Lamotrigine · DIN 02542757 · $0.4107 Lamotrigine · DIN 02343037 · $0.4107 Lamotrigine · DIN 02428229 · $0.4107 Mylan-Lamotrigine · DIN 02265516 · $0.4107 PMS-Lamotrigine · DIN 02246899 · $0.4107 Teva-Lamotrigine · DIN 02248234 · $0.4107
Shortage status: resolved shortage (ended 2018-03-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02142112
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lamotrigine · DIN 02343037 · 150mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lamotrigine · DIN 02343037 Manufacturer: Sanis Health Inc.; listing date 2011-08-04 Health Canada: Marketed since 2010-02-16 · brand LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 150 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Lamotrigine: Formulary list price $0.4107/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4107 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82852 · Verify on the e-Formulary ↗ (DIN 02343037)

Source record
DIN 02343037: Lamotrigine Raw flags: sec3=Y Item: 281200060; group id 432; item number 1081; lccId None; manufacturer id SAI Source form: Tab; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.4107; ministry $0.4107 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02343037 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82852
Interchangeable products
Apo-Lamotrigine · DIN 02245210 · $0.4107 Auro-Lamotrigine · DIN 02381370 · $0.4107 Jamp Lamotrigine · DIN 02542757 · $0.4107 Lamictal · DIN 02142112 · $0.4107 Lamotrigine · DIN 02428229 · $0.4107 Mylan-Lamotrigine · DIN 02265516 · $0.4107 PMS-Lamotrigine · DIN 02246899 · $0.4107 Teva-Lamotrigine · DIN 02248234 · $0.4107
Shortage status: resolved shortage (ended 2026-03-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02343037
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Lamotrigine · DIN 02428229 · 150mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Lamotrigine · DIN 02428229 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-08-28 Health Canada: Marketed since 2014-10-08 · brand LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 150 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Lamotrigine: Formulary list price $0.4107/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4107 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91270 · Verify on the e-Formulary ↗ (DIN 02428229)

Source record
DIN 02428229: Lamotrigine Raw flags: sec3=Y Item: 281200060; group id 432; item number 1081; lccId None; manufacturer id SIV Source form: Tab; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.4107; ministry $0.4107 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02428229 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91270
Interchangeable products
Apo-Lamotrigine · DIN 02245210 · $0.4107 Auro-Lamotrigine · DIN 02381370 · $0.4107 Jamp Lamotrigine · DIN 02542757 · $0.4107 Lamictal · DIN 02142112 · $0.4107 Lamotrigine · DIN 02343037 · $0.4107 Mylan-Lamotrigine · DIN 02265516 · $0.4107 PMS-Lamotrigine · DIN 02246899 · $0.4107 Teva-Lamotrigine · DIN 02248234 · $0.4107
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02428229
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mylan-Lamotrigine · DIN 02265516 · 150mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mylan-Lamotrigine · DIN 02265516 Manufacturer: Mylan Pharmaceuticals ULC; listing date 2005-07-14 Health Canada: Marketed since 2009-10-26 · brand MYLAN-LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 150 MG · company Mylan pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Mylan-Lamotrigine: Formulary list price $0.4107/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4107 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75097 · Verify on the e-Formulary ↗ (DIN 02265516)

Source record
DIN 02265516: Mylan-Lamotrigine Raw flags: sec3=Y Item: 281200060; group id 432; item number 1081; lccId None; manufacturer id MYL Source form: Tab; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.4107; ministry $0.4107 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02265516 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75097
Interchangeable products
Apo-Lamotrigine · DIN 02245210 · $0.4107 Auro-Lamotrigine · DIN 02381370 · $0.4107 Jamp Lamotrigine · DIN 02542757 · $0.4107 Lamictal · DIN 02142112 · $0.4107 Lamotrigine · DIN 02343037 · $0.4107 Lamotrigine · DIN 02428229 · $0.4107 PMS-Lamotrigine · DIN 02246899 · $0.4107 Teva-Lamotrigine · DIN 02248234 · $0.4107
Shortage status: resolved shortage (ended 2026-02-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02265516
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Lamotrigine · DIN 02246897 · 25mg · tablet

General benefitDormant since 2025-08-01 · checked 2026-09-02 · What does dormant mean?
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Lamotrigine · DIN 02246897 Manufacturer: Pharmascience Inc.; listing date 2004-04-06 Health Canada: Dormant since 2025-08-01 · brand PMS-LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 25 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Lamotrigine: Formulary list price $0.0698/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.0698 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71124 · Verify on the e-Formulary ↗ (DIN 02246897)

Source record
DIN 02246897: PMS-Lamotrigine Raw flags: sec3=Y Item: 281200055; group id 432; item number 1079; lccId None; manufacturer id PMS Source form: Tab; strength: 25mg Recorded listing: General benefit Source prices (unrounded): $0.0698; ministry $0.0698 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246897 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71124
Interchangeable products
Apo-Lamotrigine · DIN 02245208 · $0.0698 Auro-Lamotrigine · DIN 02381354 · $0.0698 Jamp Lamotrigine · DIN 02542730 · $0.0698 Lamictal · DIN 02142082 · $0.0698 Lamotrigine · DIN 02343010 · $0.0698 Lamotrigine · DIN 02428202 · $0.0698 Mylan-Lamotrigine · DIN 02265494 · $0.0698 Ratio-Lamotrigine · DIN 02243352 · $0.0698 Teva-Lamotrigine · DIN 02248232 · $0.0698
Shortage status: discontinued (2025-05-12, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246897
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-08-01 — choose a marketed DIN from the same-category list.

PMS-Lamotrigine · DIN 02246898 · 100mg · tablet

General benefitDormant since 2025-08-01 · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Lamotrigine · DIN 02246898 Manufacturer: Pharmascience Inc.; listing date 2004-04-06 Health Canada: Dormant since 2025-08-01 · brand PMS-LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 100 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Lamotrigine: Formulary list price $0.2787/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2787 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71125 · Verify on the e-Formulary ↗ (DIN 02246898)

Source record
DIN 02246898: PMS-Lamotrigine Raw flags: sec3=Y Item: 281200059; group id 432; item number 1080; lccId None; manufacturer id PMS Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.2787; ministry $0.2787 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246898 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71125
Interchangeable products
Apo-Lamotrigine · DIN 02245209 · $0.2787 Auro-Lamotrigine · DIN 02381362 · $0.2787 Jamp Lamotrigine · DIN 02542749 · $0.2787 Lamictal · DIN 02142104 · $0.2787 Lamotrigine · DIN 02343029 · $0.2787 Lamotrigine · DIN 02428210 · $0.2787 Mylan-Lamotrigine · DIN 02265508 · $0.2787 Teva-Lamotrigine · DIN 02248233 · $0.2787
Shortage status: resolved shortage (ended 2023-01-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246898
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-08-01 — choose a marketed DIN from the same-category list.

PMS-Lamotrigine · DIN 02246899 · 150mg · tablet

General benefitDormant since 2025-08-01 · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Lamotrigine · DIN 02246899 Manufacturer: Pharmascience Inc.; listing date 2004-04-06 Health Canada: Dormant since 2025-08-01 · brand PMS-LAMOTRIGINE · ATC N03AX09 LAMOTRIGINE · form Tablet · route Oral · ingredients LAMOTRIGINE 150 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Lamotrigine: Formulary list price $0.4107/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.4107 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71126 · Verify on the e-Formulary ↗ (DIN 02246899)

Source record
DIN 02246899: PMS-Lamotrigine Raw flags: sec3=Y Item: 281200060; group id 432; item number 1081; lccId None; manufacturer id PMS Source form: Tab; strength: 150mg Recorded listing: General benefit Source prices (unrounded): $0.4107; ministry $0.4107 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02246899 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=71126
Interchangeable products
Apo-Lamotrigine · DIN 02245210 · $0.4107 Auro-Lamotrigine · DIN 02381370 · $0.4107 Jamp Lamotrigine · DIN 02542757 · $0.4107 Lamictal · DIN 02142112 · $0.4107 Lamotrigine · DIN 02343037 · $0.4107 Lamotrigine · DIN 02428229 · $0.4107 Mylan-Lamotrigine · DIN 02265516 · $0.4107 Teva-Lamotrigine · DIN 02248234 · $0.4107
Shortage status: discontinued (2025-05-12, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246899
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-08-01 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:12 Anticonvulsants) and how they are covered

Matched class: 28:12 Anticonvulsants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLONAZEPAM, DIVALPROEX SODIUM, ETHOSUXIMIDE, VALPROATE SODIUM Some products covered without a code (check the product listing): CARBAMAZEPINE, GABAPENTIN, PHENYTOIN (DIPHENYLHYDANTOIN), PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM, PREGABALIN, PRIMIDONE, TOPIRAMATE, VALPROIC ACID 28:12 Anticonvulsants

TOPIRAMATE

· 54 products · Limited Use, codes 321 (2), Off-Formulary Interchangeable, not an ODB benefit (3), General benefit (49) · strengths: 15mg, 25mg, 50mg, 100mg, 200mg · Sprinkle Cap, Tab

BRIVARACETAM

· 12 products · Limited Use, codes 548 · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Tab

CENOBAMATE

· 9 products · Limited Use, codes 719 · strengths: 12.5mg, 25mg, 50mg, 100mg, 150mg, 200mg, 12.5mg & 25mg, 50mg & 100mg, 150mg & 200mg · Tab, Tab - (Starter Kit)

LACOSAMIDE

· 44 products · Limited Use, codes 430 · strengths: 50mg, 100mg, 150mg, 200mg · Tab

LEVETIRACETAM

· 49 products · Limited Use, codes 640, 705 (3), Limited Use, codes 473 (46) · strengths: 100mg/mL, 250mg, 500mg, 750mg, 1000mg · Oral Sol, Tab

PERAMPANEL

· 12 products · Limited Use, codes 430, 564 · strengths: 2mg, 4mg, 6mg, 8mg, 10mg, 12mg · Tab

CARBAMAZEPINE

· 15 products · Listed, not a benefit (3), General benefit (6), Temporary benefit (2), Limited Use, codes 67 (4) · strengths: 100mg, 200mg, 400mg, 100mg/5mL · Chew Tab, ER Tab, LA Tab, Oral Susp, Tab

CLONAZEPAM

· 9 products · General benefit · strengths: 0.5mg, 2mg · Tab

DIVALPROEX SODIUM

· 9 products · General benefit · strengths: 125mg, 250mg, 500mg · Ent Tab

ETHOSUXIMIDE

· 4 products · General benefit · strengths: 250mg, 50mg/mL · Cap, O/L

PHENYTOIN (DIPHENYLHYDANTOIN)

· 4 products · General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (2), General benefit (2) · strengths: 6mg/mL, 25mg/mL, 50mg · O/L, Tab

PHENYTOIN (DIPHENYLHYDANTOIN) SODIUM

· 4 products · General benefit (3), Limited Use, codes 481, 657 (1) · strengths: 30mg, 100mg, 50mg/mL · Cap, Inj Sol (Preservative Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:12 and 11 more
Full class listing Related classes: 28:08 Analgesics, 28:10 Opiate Antagonists, 28:16 Psychotherapeutic Agents, 28:20 C.N.S. Stimulants, 28:24 Sedatives and Hypnotics, 28:36 Antiparkinsonian Agents, 28:92 Miscellaneous Central Nervous System Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS Adults ( 18 years of age) LAMICTAL (lamotrigine) is indicated: • as adjunctive therapy for the management of epilepsy not satisfactorily controlled by conventional therapy; • for use as monotherapy following withdrawal of concomitant antiepileptic drugs; • as adjunctive therapy for the management of the seizures associated with Lennox-Gastaut syndrome. 1.1 Pediatrics Pediatrics (<18 years of age) LAMICTAL (lamotrigine) is indicated as adjunctive therapy for the management of the seizures associated with Lennox-Gastaut syndrome. LAMICTAL is not recommended in children weighing less than 9 kg (see 4 DOSAGE AND ADMINISTRATION). Safety and efficacy in patients below the age of 16 years, other than those with Lennox-Gastaut Syndrome, have not been established. 1.2 Geriatrics Geriatrics (> 65 years of age): No dosage adjustment is required in patients over 65 years of age. https://pdf.hres.ca/dpd_pm/00080062.PDF PM date: November 21, 1994 Source product: LAMICTAL; DIN 02142082; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

PMS-Lamotrigine · DIN 02246897 Shortage status: discontinued (2025-05-12, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246897

Check this DIN again

PMS-Lamotrigine · DIN 02246899 Shortage status: discontinued (2025-05-12, reported by PHARMASCIENCE INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02246899

Check this DIN again
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, Sep 10, 2026 ↗)

Prepare an Exceptional Access request

SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE

Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.

EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026

EAP fax: In Ontario: 1-866-811-9908 or 416-327-7526 (Toronto area). Outside Ontario: 1-833-905-4260. Source; updated September 15, 2026

Posted turnaround and Telephone Request Service scope
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Source; updated September 15, 2026

Lamotrigine (chewable) (Lamictal)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: See the ministry wording below; no separate indication heading is held.

Ministry criteria corpus 2025-01-01; page 31

Lamotrigine (chewable) Brand(s): Lamictal DOSAGE FORM/ STRENGTH: 5 mg chewable tablet
For the adjunctive therapy for children over 2 years of age who are suffering from refractory seizures associated with Lennox-Gastaut syndrome, and who have previously tried other antiepileptic drugs.
Duration of Approval: 1 year

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.